Treatment
ONC201 clinical trials
We’re tracking 6 recruiting studies that include ONC201, each written for real people, not researchers, below.
Recruiting studies
- NCT05580562RecruitingPhase 3
ONC201 for newly diagnosed H3 K27M brain tumor after radiation
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Phoenix, ArizonaAges Any age - NCT04055649RecruitingPhase 2
Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Detroit, MichiganAges 18 years+ - NCT05542407RecruitingPhase 1
ONC201 plus atezolizumab for endometrial cancer and obesity
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT05476939RecruitingPhase 3
BIOMEDE 2.0 trial for DIPG and similar brainstem gliomas
This phase 3 study tests targeted treatments (ONC201 or everolimus) for children with DIPG or similar diffuse midline brain tumors, based on the tumor’s genetic markers. It aims to improve outcomes by matching treatment to the tumor biology and comparing approaches in a randomized way.
AarhusAges 6 months+ - NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Birmingham, AlabamaAges 2–39 - NCT05630794RecruitingPhase 1
Test ONC201 to prevent colorectal polyp return in high-risk people
This Phase 1 study tests whether ONC201 is safe and may help prevent colorectal polyps (adenomas) from coming back. You’d also undergo planned colon/rectum camera exams to check for new or changing polyps.
Ann Arbor, MichiganAges 18 years+
What ONC201 is being studied for
Conditions with recruiting ONC201 studies.
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Ovarian Carcinoma
- Recurrent Diffuse Intrinsic Pontine Glioma
Common questions
- Are there clinical trials studying ONC201?
- Yes. Clin2 currently lists 6 recruiting studies that include ONC201, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a ONC201 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is ONC201 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether ONC201 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.